The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends
- PMID: 36482957
- PMCID: PMC9714996
- DOI: 10.53854/liim-3004-2
The emergence of SARS-CoV-2 Omicron subvariants: current situation and future trends
Abstract
The SARS-CoV-2 Omicron variant (B.1.1.529) has been the most recent variant of concern (VOC) established by the World Health Organization (WHO). Because of its greater infectivity and immune evasion, this variant quickly became the dominant type of circulating SARS-CoV-2 worldwide. Our literature review thoroughly explains the current state of Omicron emergence, particularly by comparing different omicron subvariants, including BA.2, BA.1, and BA.3. Such elaboration would be based on structural variations, mutations, clinical manifestation, transmissibility, pathogenicity, and vaccination effectiveness. The most notable difference between the three subvariants is the insufficiency of deletion (Δ69-70) in the spike protein, which results in a lower detection rate of the spike (S) gene target known as (S) gene target failure (SGTF). Furthermore, BA.2 had a stronger affinity to the human Angiotensin-converting Enzyme (hACE2) receptor than other Omicron sub-lineages. Regarding the number of mutations, BA.1.1 has the most (40), followed by BA.1, BA.3, and BA.3 with 39, 34, and 31 mutations, respectively. In addition, BA.2 and BA.3 have greater transmissibility than other sub-lineages (BA.1 and BA.1.1). These characteristics are primarily responsible for Omicron's vast geographical spread and high contagiousness rates, particularly BA.2 sub-lineages.
Keywords: BA.2 sub-lineages; COVID-19; Omicron variant; SARS-CoV-2; immune evasion; spike protein; transmissibility.
Conflict of interest statement
Declaration of competing interest Authors have no conflict of interest, except AJ Rodriguez-Morales, speaker/consultant for Amgen, AstraZeneca, and Valneva, concerning COVID-19 vaccines.
Figures




Similar articles
-
Omicron (BA.1) and sub-variants (BA.1.1, BA.2, and BA.3) of SARS-CoV-2 spike infectivity and pathogenicity: A comparative sequence and structural-based computational assessment.J Med Virol. 2022 Oct;94(10):4780-4791. doi: 10.1002/jmv.27927. Epub 2022 Jun 16. J Med Virol. 2022. PMID: 35680610 Free PMC article.
-
Immune Evasion of SARS-CoV-2 Omicron Subvariants.Vaccines (Basel). 2022 Sep 16;10(9):1545. doi: 10.3390/vaccines10091545. Vaccines (Basel). 2022. PMID: 36146623 Free PMC article.
-
Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion.Microb Pathog. 2022 Sep;170:105699. doi: 10.1016/j.micpath.2022.105699. Epub 2022 Aug 6. Microb Pathog. 2022. PMID: 35944840 Free PMC article. Review.
-
The evolution of the spike protein and hACE2 interface of SARS-CoV-2 omicron variants determined by hydrogen bond formation.Brief Funct Genomics. 2023 May 18;22(3):291-301. doi: 10.1093/bfgp/elac053. Brief Funct Genomics. 2023. PMID: 36723978
-
The Epidemiological Features of the SARS-CoV-2 Omicron Subvariant BA.5 and Its Evasion of the Neutralizing Activity of Vaccination and Prior Infection.Vaccines (Basel). 2022 Oct 11;10(10):1699. doi: 10.3390/vaccines10101699. Vaccines (Basel). 2022. PMID: 36298564 Free PMC article. Review.
Cited by
-
Current hotspot and study trend of innate immunity in COVID-19: a bibliometric analysis from 2020 to 2022.Front Immunol. 2023 May 10;14:1135334. doi: 10.3389/fimmu.2023.1135334. eCollection 2023. Front Immunol. 2023. PMID: 37234160 Free PMC article.
-
SARS-CoV-2 surveillance in a veterinary health system provides insight into transmission risks.J Am Vet Med Assoc. 2023 Oct 13;262(1):93-99. doi: 10.2460/javma.23.05.0229. Print 2024 Jan 1. J Am Vet Med Assoc. 2023. PMID: 38103381 Free PMC article.
-
Genetic Diversity and Spatiotemporal Distribution of SARS-CoV-2 Variants in Guinea: A Meta-Analysis of Sequence Data (2020-2023).Viruses. 2025 Jan 31;17(2):204. doi: 10.3390/v17020204. Viruses. 2025. PMID: 40006959 Free PMC article.
-
Effectiveness of booster vaccination with inactivated COVID-19 vaccines against SARS-CoV-2 Omicron BA.2 infection in Guangdong, China: a cohort study.Front Immunol. 2023 Oct 17;14:1257360. doi: 10.3389/fimmu.2023.1257360. eCollection 2023. Front Immunol. 2023. PMID: 37915583 Free PMC article.
-
Pan-American Guidelines for the treatment of SARS-CoV-2/COVID-19: a joint evidence-based guideline of the Brazilian Society of Infectious Diseases (SBI) and the Pan-American Association of Infectious Diseases (API).Ann Clin Microbiol Antimicrob. 2023 Aug 7;22(1):67. doi: 10.1186/s12941-023-00623-w. Ann Clin Microbiol Antimicrob. 2023. PMID: 37550690 Free PMC article.
References
-
- COVID Live-Coronavirus Statistics-Worldometer. [accessed 22 Oct2022]. https://www.worldometers.info/coronavirus/
-
- Kannan S, Shaik Syed Ali P, Sheeza A. Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology. Eur Rev Med Pharmacol Sci. 2021;25:4405–4412. - PubMed
-
- Kannan S, Shaik Syed Ali P, Sheeza A. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021;25:8019–8022. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous